Seroatlas · Human Serome Atlas

SLC29A2

Equilibrative nucleoside transporter 2

Also known as: DER12, ENT2, HNP36, S29A2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q14542
Gene: SLC29A2
Ensembl: ENSG00000174669
Chromosome: 11
Canonical length: 456 aa
Protein class: Metabolic proteins, Predicted membrane proteins, Transporters

OverviewNCBI Gene

The uptake of nucleosides by transporters, such as SLC29A2, is essential for nucleotide synthesis by salvage pathways in cells that lack de novo biosynthetic pathways. Nucleoside transport also plays a key role in the regulation of many physiologic processes through its effect on adenosine concentration at the cell surface (Griffiths et al., 1997 [PubMed 9396714]).[supplied by OMIM, Nov 2008]

Canonical amino-acid sequenceUniProt

456 residues, UniProt reviewed canonical sequence.

>Q14542|SLC29A2
     1  MARGDAPRDS YHLVGISFFI LGLGTLLPWN FFITAIPYFQ ARLAGAGNST ARILSTNHTG
    61  PEDAFNFNNW VTLLSQLPLL LFTLLNSFLY QCVPETVRIL GSLLAILLLF ALTAALVKVD
   121  MSPGPFFSIT MASVCFINSF SAVLQGSLFG QLGTMPSTYS TLFLSGQGLA GIFAALAMLL
   181  SMASGVDAET SALGYFITPC VGILMSIVCY LSLPHLKFAR YYLANKSSQA QAQELETKAE
   241  LLQSDENGIP SSPQKVALTL DLDLEKEPES EPDEPQKPGK PSVFTVFQKI WLTALCLVLV
   301  FTVTLSVFPA ITAMVTSSTS PGKWSQFFNP ICCFLLFNIM DWLGRSLTSY FLWPDEDSRL
   361  LPLLVCLRFL FVPLFMLCHV PQRSRLPILF PQDAYFITFM LLFAVSNGYL VSLTMCLAPR
   421  QVLPHEREVA GALMTFFLAL GLSCGASLSF LFKALL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC29A2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 11
Mean surface accessibility (rSASA): 0.29
Highest tissue expression: 85 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 85 nTPM
tongue: 44 nTPM
cerebellum: 13 nTPM
parathyroid gland: 12 nTPM
heart muscle: 12 nTPM
stomach: 8.9 nTPM

Single-cell type

myonuclei: 173 nCPM
thymic myoid cells: 129 nCPM
cytotrophoblasts: 64 nCPM
bergmann glia: 43 nCPM
migrating cytotrophoblasts: 41 nCPM
cardiomyocytes: 38 nCPM

Immune cell

naive CD8 T-cell: 1.8 nTPM
memory CD8 T-cell: 1.7 nTPM
naive CD4 T-cell: 1.7 nTPM
gdT-cell: 1.3 nTPM
memory CD4 T-cell: 0.7 nTPM
naive B-cell: 0.7 nTPM

Brain region

cerebellum: 26 nTPM
pons: 22 nTPM
midbrain: 20 nTPM
medulla oblongata: 20 nTPM
thalamus: 18 nTPM
cerebral cortex: 16 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.41
gnomAD pLI: 0
gnomAD missense Z: 0.48
DepMap mean gene effect: -0.25
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC29A2 as an antibody target. Whether an autoantibody or antibody against SLC29A2 could matter depends on whether native SLC29A2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC29A2 is annotated at the cell surface, where native SLC29A2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC29A2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...